Effect of obesity on pharmacokinetics and biologic effect of interferon-α in hepatitis C

Digestive Diseases and Sciences

Volumn 42, Issue 1, 1997, Pages 178-185

  Lam, Nancy P ^a   Pitrak, David ^b   Speralakis, Rita ^b   Lau, Alan H ^b   Wiley, Thelma E ^b   Layden, Thomas J ^b  

^a Chicago College of Pharmacy   (United States)

^b NONE

Author keywords

2',5' oligoadenylate synthetase; chronic hepatitis C; histologic activity index; interferon ; obesity

Indexed keywords

ALPHA INTERFERON;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; BODY WEIGHT; CHRONIC HEPATITIS; CLINICAL ARTICLE; DRUG BLOOD LEVEL; FEMALE; GENOTYPE; HEPATITIS C; HISTOLOGY; HUMAN; MALE; OBESITY; PHARMACOKINETICS; PRIORITY JOURNAL;

2',5'-OLIGOADENYLATE SYNTHETASE; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CHRONIC DISEASE; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2B; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; OBESITY; RNA, VIRAL;

EID: 0031025974     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018865928308     Document Type: Article

References (40)

1. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, Van Thiel DH, Tamburro CF, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A, Hepatitis Interventional Therapy Group: Treatment of chronic hepatitis C with recombinant interferon alfa: A multicenter, randomized, controlled study. N Engl J Med 321:1501-1506, 1989
2. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH: Recombinant interferon alfa therapy for chronic hepatitis C; a randomized double-blind placebo-controlled trial. N Engl J Med 321:1506-1510, 1989
3. Lau JYN, David GL, Kniffen J, Qian KP, Urdea MS, Chan CS, Mizokami M, Neuwald PD, Wilber JC: Significance of serum hepatitis C virus RNA levels in chronic hepatitis. Lancet 341:1501-1504, 1993
4. Hagiwara H, Hayashi N, Mita E, Takehara J, Kasahara A, Hideyuki F, Kamada T: Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 104:877-893, 1993
5. Shindo M, DiBisceglie AM, Hoofnagle JH: Long term follow up of patients with chronic hepatitis C treated with alpha-interferon. Hepatology 15:1013-1016, 1992
6. Okada S, Akahane Y, Suzuki H, Okamoto H, Mishiro S: The degree of variability in the amino terminal regions of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 16:619-624, 1992
7. Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, Hashimoto M, Iwasaki S, Kobayashi M, Hiromitsu K: Factors predictive of response to interferon-α therapy in hepatitis C virus infection. Hepatology 19:1088-1094, 1994
8. Yoshioka K, Kakumu S, Wakita T, Ishikama T, Itoh Y, Takayanagi M, Higashi Y, Shibata M, Morishima T: Detection of hepatitis C virus by polymerase chain reaction and response to interferon-α therapy: Relationship to genotypes of hepatitis C virus. Hepatology 16:293-299, 1992
9. Perez R, Pravia R, Linares A, Rodriguez M, Lombrana JLS, Suarez A, Riestra S, Navascues CA, Rodrigo L: Response related factors in recombinant interferon alfa-2b treatment of chronic hepatitis C. Gut 34(suppl):S139-S140, 1993
10. Battezzati PM, Podda M, Bruno S, Zuin M, Crosignani A, Camisasca M, Chiesa A, Petroni ML, Russo A, Gallotti P, et al: Factors predicting early response to treatment with recombinant interferon alpha-2a in chronic non-A, non-B hepatitis. Preliminary report of a long-term trial. Ital J Gastroenterol 24:481-484, 1992
11. Serfaty L, Giral P, Loria A, Andreani T, Legendre C, Poupon R: Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol 21:12-17, 1994
12. Van Thiel DH, Gavaler JS, Wright HI, Friedlander L: Responses to alfa interferon therapy are influenced by the iron content of liver. Gastroenterology A904, 1992 (abstract)
13. Lam NP, DeGuzman LJ, Pitrak D, Layden TJ: Clinical and histologic predictors of response to interferon-α in patients with chronic hepatitis C viral infection. Dig Dis Sci 39(12):2660-2664, 1994
14. Camps J, Crisostomo S, Garcia-Granero M, Riezu-Boj JI, Civeira MP, Prieto J: Prediction of the response of chronic hepatitis C to interferon alfa: A statistical analysis of pretreatment variables. Gut 34:1714-1717, 1993
15. Knodell RG, Ishak KG, Black WC, Chen TS, Criag R, Kaplowitz N, Kiernan TW, Wollman J: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431-435, 1981
16. Devine BJ: Clinical pharmacy case studies - gentamicin therapy. Drug Intell Clin Pharm 8:650-655, 1974
17. Schattner A, Merlin G, Wallach D, Rosenberg H, Bino T, Hahn T, Levin S, Revel M: Monitoring of interferon therapy by assay of (2′-5′) oligoisoadenylate synthetase in human peripheral white blood cells. J Interferon Res 1:587-594, 1981
18. Meritt JA, Borden EC, Ball LA: Measurement of 2′-5′ oligoadenylate synthetase during treatment with interferon alpha. J Interferon Res 5:191-198, 1985
19. Witter F, Barouki F, Griffin D, Nadler P, Woods A, Wood D, Lietman P: Biologic response (antiviral) to recombinant human interferon alpha 2a as a function of dose and route of administration in healthy volunteers. Clin Pharmacol Ther 42:567-575, 1987
20. Heathcote EJ, Kim YI, Yom CK, LeBrocq J, Read SE: Interferon-associated lymphocyte 2′5′-oligoadenylate synthetase in acute and chronic viral hepatitis. Hepatology 9:105-109, 1989
21. Grossberg SE, Taylor JL, Siebenlist RE, Jameson P: Biological and immunological assays of human interferons. In Manual of Clinical Laboratory Immunology. Rose, Friedman, Fahey (eds). Washington, DC, American Society of Microbiology, 1986, pp 295-299
22. Gretch D, Lee W, Corey L: Use of aminotransferase, hepatitis C antibody, and hepatitis C polymerase chain reaction RNA assays to establish the diagnosis of hepatitis C virus infection in a diagnostic virology laboratory. J Clin Microbiol 30:2145-2149, 1992
23. Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, Sato K, Tsuda F, Miyakawa Y, Mayami M: Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infections sources. J Gen Virol 73:673-679, 1992
24. Gibaldi M, Perrier D: Pharmacokinetics. New York, Marcel Dekker, 1982
25. Wong DKH, Yim C, Naylor CD, Chen E, Sherman M, Vas S, Wanless IR, Read S, Li H, Heathcote EJ: Interferon alfa treatment of chronic hepatitis B: Randomized trial in a predominantly homosexual male population. Gastroenterology 108:165-171, 1995
26. Abernethy DR, Greenblatt DJ: Drug disposition in obese humans: An update. Clin Pharmacokinet 11:199-231, 1986
27. Bauer LA, Drew Edwards WA, Patchen Dellinger E, Simmonowitz DA: Influence of weight on aminoglycosides pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol 24:643-647, 1983
28. Lind MJ, Margison JM, Cerny T, Thatcher N, Wilkinson PM: Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution. Cancer Chemother Pharmacol 25:139-142, 1989
29. Bauer LA, Wareing-Tran C, Drew Edwards WA, Raisys V, Ferreri L, Jack R, Dellinger EP, Simonowitz D: Cimetidine clearance in the obese. Clin Pharmacol Ther 37:425-430, 1985
30. Cheymol G, Poirier JM, Barre J, Pradalier A, Dry J: Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers. J Clin Pharmacol 27:874-875, 1987
31. Wilkes L, Danziger LH, Rodvold KA: Phenobarbital pharmacokinetics in obesity: A case report. Clin Pharmacokinet 22:481-484, 1992
32. Zuccaro P, Guandalini S, Pacifici R, Pichini S, Di Martino L, Guiducci M, Giuliano M, Di Tullio MT, Pettoello-Mantovani M: Fat body mass and pharmacokinetics of 6-mercaptopurine in children with acute lymphoblastic leukemia. Ther Drug Monit 13:37-41, 1991
33. Peters M: Mechanisms of action of interferons. Semin Liver Dis 9(4):235-239, 1989
34. Baron S, Tyring SK, Fleischmann R, Coppenhaver DH, Niesel DW, Klimpel GR, Stanton J, Hughes TK: The interferons: Mechanisms of action and clinical applications. JAMA 266(10):1375-1383, 1991
35. Schattner A, Wallach D, Merlin G, Hahn T, Levin S, Revel M: Assay of an interferon-induced enzyme in white blood cells as a diagnostic aid in viral diseases. Lancet 2:497-500, 1981
36. Harrison LC, Martin FIR, Melick RA: Correlation between insulin receptor binding in isolated fat cells and insulin sensitivity in obese human subjects. J Clin Invest 58:1435-1441, 176
37. Kashiwagi AC, Bogardus C, Lillioja S, Huecksteadt TP, Brady D, Verso MA, Foley JE: In vitro insensitivity of glucose transport and antilipolysis to insulin due to receptor and postreceptor abnormalities in obese Pima Indians with normal glucose tolerance. Metabolism 33:772-777, 1984
38. Kolterman OG, Reaven GM, Olefsky JM: Relationship between in vivo insulin resistance and decreased insulin receptors in obese man. J Clin Endocrinol Metab 48:487-494, 1979
39. Kolterman OG, Insel J, Saekow M, Olefsky JM: Mechanisms of insulin resistance in human obesity. Evidence for receptor and postreceptor defects. J Clin Invest 65:1271-1284, 1980
40. Bjorntorp P, Berchtold P, Holm J: The glucose uptake of human adipose tissue in obesity. Eur J Clin Invest 1:480-488, 1971